Across TCGA pan-cancer cohorts, MYL4 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated MYL4 data layer compared with 1 for mutation status and 3 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher MYL4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYL4 expression acts as an unfavorable survival marker, although some lineages such as THCA and OV show a favorable association.
KIRP, SCLC, and STAD are the cancer types where MYL4 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.